TuHURA Biosciences (NASDAQ:HURA) Given New $12.00 Price Target at HC Wainwright

TuHURA Biosciences (NASDAQ:HURA) had its price objective cut by HC Wainwright from $13.00 to $12.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for TuHURA Biosciences’ Q3 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS and Q2 2027 earnings at ($0.09) EPS.

Other equities analysts also recently issued research reports about the company. RODMAN&RENSHAW raised TuHURA Biosciences to a “strong-buy” rating in a research report on Thursday, December 19th. Rodman & Renshaw initiated coverage on TuHURA Biosciences in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective for the company.

TuHURA Biosciences Trading Down 0.6 %

Shares of NASDAQ HURA opened at $3.38 on Thursday. The firm has a 50-day simple moving average of $3.42. TuHURA Biosciences has a 12-month low of $1.80 and a 12-month high of $7.93.

Institutional Investors Weigh In On TuHURA Biosciences

Several hedge funds have recently made changes to their positions in the business. Accent Capital Management LLC purchased a new position in TuHURA Biosciences during the fourth quarter worth about $29,000. TT Capital Management LLC purchased a new position in shares of TuHURA Biosciences during the 4th quarter worth about $41,000. Jefferies Financial Group Inc. acquired a new stake in shares of TuHURA Biosciences in the fourth quarter worth approximately $54,000. Bank of America Corp DE purchased a new stake in TuHURA Biosciences in the fourth quarter valued at approximately $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in TuHURA Biosciences during the fourth quarter worth approximately $61,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.